GI Dynamics
GI Dynamics (operating as Morphic Medical) develops RESET®, an endoscopically delivered device therapy for type 2 diabetes and obesity. The device is commercially available in the EU and UK and under U.S. clinical investigation via the STEP-1 trial, sold to specialist hospitals and endoscopy centers.
- Company typePrivate
- Founded2003
- HeadquartersLexington, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What GI Dynamics does
GI Dynamics (operating publicly as Morphic Medical, Inc.) is a medical device company founded in 2003 that develops RESET®, an endoscopically delivered device therapy intended to reduce HbA1c and weight in patients with type 2 diabetes and obesity. RESET® is positioned to bridge the gap between pharmaceutical therapy and bariatric surgery by serving patients whose disease is not adequately controlled by drugs and injections but for whom surgery is not appropriate. The underlying technology is a minimally invasive, endoscopically implanted device that the company describes as the first of its kind to target the underlying cause of type 2 diabetes; supporting assets include a registered RESET® trademark and an actively maintained patents portfolio.
The company's business model is hardware sales of the RESET® device to hospitals and outpatient endoscopy centers. Commercial sales are currently authorized only in the European Union and the United Kingdom, with a separate EU website (eu.morphicmedical.com) and regional channel partners supporting distribution. In the United States, RESET® is limited to Investigational Use, and access is restricted to enrollment in the STEP-1 clinical study via StudyType2Diabetes.com. Pricing is not publicly disclosed and is quote-based. The company employs 51-100 staff and is led by Chairman Mark Lerdal, CFO Robert Crane, and VP of Clinical and Regulatory Affairs Steve Linhares.
Cumulatively, the company has raised over $200M across 13 funding rounds from 2003 through 2019, including a $15M strategic investment by Medtronic in 2010 and a $10M round led by Crystal Amber in 2019. The firm was previously listed on the ASX under ticker GID (now delisted) and is now headquartered in Boston, Massachusetts. The company markets itself primarily through clinical evidence, conference presence (e.g., EASD 2022), earned media (including BBC News coverage), and clinical publications rather than consumer advertising, consistent with a specialist, clinical-led go-to-market motion.
GI Dynamics firmographics
Firmographics- Name
- GI Dynamics
- Legal name
- Morphic Medical, Inc.
- Website
- https://gidynamics.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- GI Dynamics (operating as Morphic Medical) develops RESET®, an endoscopically delivered device therapy for type 2 diabetes and obesity. The device is commercially available in the EU and UK and under U.S. clinical investigation via the STEP-1 trial, sold to specialist hospitals and endoscopy centers.
- Ownership category
- akta.pro rank
GI Dynamics industry classification
Industry- Product category
- Diabetes and Obesity Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Computer Systems Design Services (541512)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Services-Offices & Clinics Of Doctors Of Medicine (8011)
- akta.pro primary industry
- Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF)
- akta.pro secondary industries
- Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN), Type 2 Diabetes Care (HLAKADAC)
Keywords
Where GI Dynamics is headquartered
LocationHeadquarters
- HQ city
- Lexington
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
GI Dynamics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others
Revenue model
- Medical Device Sales (RESET®): Revenue generated from sale of the RESET® endoscopic device to hospitals and endoscopy centers. Commercial sales currently authorized in the EU and UK; U.S. revenue limited to investigational use. Pricing not publicly disclosed.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
GI Dynamics product offering
Product offeringCore offering
GI Dynamics develops and commercializes RESET®, an endoscopically delivered medical device therapy for the treatment of type 2 diabetes and obesity. RESET® is positioned as the first device of its kind designed to target the underlying cause of type 2 diabetes and to bridge the gap between pharmaceutical therapy and bariatric surgery by reducing HbA1c and weight in patients underserved by drugs and injections. The device is approved for sale in the EU and UK and is limited to Investigational Use in the United States, where enrollment in the STEP-1 clinical study is ongoing.
Product overview
The provided source material does not describe any GI Dynamics products or services. The news article discusses the broader bariatric surgery devices market, referencing Duomed Group's acquisition of REY Médical SA and Johnson & Johnson MedTech's launch of the ECHELON ENDOPATH staple line reinforcement device, but does not mention any GI Dynamics offering. The webpage describes Morphic Medical's RESET® therapy for type 2 diabetes, which is a Morphic Medical product rather than a GI Dynamics product based on the source text.
Differentiator
Problem solved
Functional benefit
Brands
- RESET®: World's first endoscopically delivered device therapy for the treatment of type 2 diabetes and obesity, designed to bridge the gap between pharmaceuticals and surgery.
Products and services
- RESET® Therapy RESET® is the first endoscopically delivered device therapy for the treatment of type 2 diabetes and obesity. It is intended to reduce HbA1c and weight in patients whose type 2 diabetes and weight are not adequately controlled by drugs and injections but for whom bariatric surgery is not an appropriate option. The device is approved for sale in the EU and UK and is limited to Investigational Use in the United States, where it is being evaluated in the STEP-1 clinical study.
Quantifiable outcome
- Targets reduction of HbA1c and weight in type 2 diabetes and obesity patients underserved by drugs/injections and ineligible for surgery
- +1 more outcomes
Companies that use GI Dynamics
Customer profileSegments3 records
Ideal customer profiles2 records
GI Dynamics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
GI Dynamics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Duomed Group / REY Médical SAminorNot a direct partnership with the subject company; referenced in source news as a competitive/distribution signal in the bariatric surgery devices market. In July 2024, Belgium-based Duomed Group acquired Swiss distributor REY Médical SA to expand its distribution network in Switzerland for minimally invasive surgical equipment. Included as market-context signal for the broader category in which the subject company competes.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
GI Dynamics competitors and assessment
Company assessmentDirect peers
- Fractyl Health: Fractyl Health develops Revita DMR, an endoscopic duodenal mucosal resurfacing procedure for type 2 diabetes — the most direct mechanistic and clinical competitor to RESET® in the endoscopic T2D device category, targeting the same treatment-gap patient population.
- Apollo Endosurgery: Apollo Endosurgery markets endoscopic bariatric/metabolic devices including the Orbera intragastric balloon and OverStitch endoscopic suturing system, competing with RESET® for the same endoscopist channel and obesity-with-comorbid-T2D patient segment.
- USGI Medical: USGI Medical develops endoscopic tissue approximation and bariatric/metabolic devices (e.g., g-Cath EZ Suture System), operating in the same endoscopic bariatric/metabolic procedure category as RESET® and targeting similar specialist physician channels.
- Allurion Technologies: Allurion markets the Allurion Gastric Balloon, a procedureless (swallowable) endoscopic weight-loss device, competing with RESET® for endoscopy-center adoption and the obesity/metabolic disease patient segment.
- ReShape Lifesciences: ReShape Lifesciences markets the LAP-BAND system and previously the ReShape intragastric balloon, positioning itself as an endoscopic/surgical obesity-device competitor to RESET® for patients with obesity and metabolic comorbidities.
Emerging players
- Spatz FGIA (Spatz Medical): Spatz3 is an adjustable endoscopic intragastric balloon competing in the endoscopic bariatric space alongside RESET®'s obesity indication, with overlapping specialist-channel dynamics but a more niche commercial footprint.
- Aspire Bariatrics: Aspire Bariatrics developed the AspireAssist aspiration therapy, a percutaneous/endoscopic weight-loss device positioned between pharmacotherapy and bariatric surgery in a similar treatment-gap niche to RESET®.
Broad incumbents
- Medtronic: Medtronic is a historical GI Dynamics investor (2010, $15M) and a dominant bariatric/metabolic medtech incumbent with surgical stapling, hernia, and obesity-intervention portfolios, making it both a strategic channel partner and a potential acquirer.
- Johnson & Johnson MedTech: J&J MedTech (through J&J Development Corporation as a 2009 investor in GI Dynamics) operates a broad minimally invasive and bariatric surgery portfolio (e.g., ECHELON ENDOPATH), positioning it as a strategic acquirer and incumbent in the same end-procedure category.
Others
- Novo Nordisk: Novo Nordisk markets Ozempic, Wegovy, and Rybelsus (GLP-1 agonists) — the principal pharmacologic competitor shaping the T2D/obesity treatment landscape that RESET® must position against as a non-pharmacologic device alternative.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
GI Dynamics social profiles
Digital presenceGI Dynamics financial estimates
Financial estimateRevenue estimate
Valuation estimate
GI Dynamics leadership team
Management profileNumber of profiles
Profiles3 records
GI Dynamics funding detail
Funding detailFunding overview
Funding rounds13 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GI Dynamics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GI Dynamics
What does GI Dynamics do?
GI Dynamics develops and commercializes RESET®, an endoscopically delivered medical device therapy for the treatment of type 2 diabetes and obesity. RESET® is positioned as the first device of its kind designed to target the underlying cause of type 2 diabetes and to bridge the gap between pharmaceutical therapy and bariatric surgery by reducing HbA1c and weight in patients underserved by drugs and injections. The device is approved for sale in the EU and UK and is limited to Investigational Use in the United States, where enrollment in the STEP-1 clinical study is ongoing.
Is GI Dynamics a public or private company?
GI Dynamics is a private company. It is classified as venture growth investor backed and is currently operating.
When was GI Dynamics founded?
GI Dynamics was founded in 2003. It employs 51 to 100 people.
Where is GI Dynamics based?
GI Dynamics is headquartered in Lexington, United States, in the North America region.
How does GI Dynamics make money?
One revenue line is on record: medical Device Sales (RESET®).
Who are GI Dynamics's main competitors?
Direct peers on record are Fractyl Health, Apollo Endosurgery, USGI Medical, Allurion Technologies and ReShape Lifesciences. Emerging players are Spatz FGIA (Spatz Medical) and Aspire Bariatrics. Broad incumbents are Medtronic and Johnson & Johnson MedTech. Novo Nordisk is listed as an others.
Does GI Dynamics have an API?
No public API is recorded for GI Dynamics.
What industry is GI Dynamics in?
GI Dynamics's product category is Diabetes and Obesity Medical Devices. Its primary akta.pro industry code is HLAHAHAF, Automated Insulin Delivery (AID) / Closed-Loop Systems, with a secondary code of HLAHADAN, Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools). Its NAICS code is 339113 and its SIC code is 3841.